Date: 23-March-2019  
Source:  Guangdong Tencent News

TAEST16001 of Xiangxue has been the first TCR-T IND (Investigational New Drug) in China approved by NMPA (National Medical Products Administration).

With independent intellectual property rights, Xiangxue Life Sciences has established a platform to develop cell-based therapies that take advantage of the unique attributes of TCR mediated target recognition. As first product of company, TAEST16001 reaches the international advanced level. Being considered of the highly effective technology for tumor vaccination, TCR-T has shown the potential to improve cure rate and to save lives of patients with malignant tumor.

广州市香雪制药股份有限公司子公司广东香雪精准医疗技术有限公司向国【guó】家药品监督管理局提交的TAEST16001注射液新药临床注册申请已获得国内首个TCR-T临床试验许可。

香雪精准已建立TCR-T完整的技术平台及工艺，具有完整【zhěng】的自主知识产权，TAEST16001注射液是香雪精准研发【fā】管线的第一个产品，达到了国际先进水平。特异性T细胞受体免疫治疗技术（TCR-T）是目前在肿瘤免疫治【zhì】疗领域具有显著疗效的先进技术，可实现疾病的个体化精准治疗，大大提高肿瘤的治愈率，从而有望从根本上治愈恶性肿瘤这一顽疾。